InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,235.48
(
-0.60%
)
US TECH 100
18,014.00
(
-0.27%
)
Dow Jones
38,111.48
(
-0.86%
)
Brent Oil
81.99
(
0.04%
)
Bitcoin
67,874.40
(
-0.71%
)
Post# of 251981
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 829
Posts 119731
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: Mufaso post# 251271

Monday, 05/13/2024 12:44:53 PM

Monday, May 13, 2024 12:44:53 PM

Post# of 251981
TERN-601:

https://finance.yahoo.com/news/terns-pharmaceuticals-reports-first-quarter-120500965.html

• Phase 1 first-in-human clinical trial of Terns’ lead oral GLP-1 receptor agonist in obese and overweight participants is progressing

• The multiple ascending dose (MAD) portion of the study is underway, testing once-daily administration of TERN-601, and is on track to report top-line 28-day weight loss data in the second half of 2024

• Preliminary safety findings from the ongoing, blinded Phase 1 SAD/MAD study have been unremarkable to date with no observations of liver enzyme elevations, drug induced liver injury or discontinuations due to treatment-related adverse events

Why is this compound in your less interesting, “May surprise” grouping? TIA

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up